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NO plays critical roles in vascular function. We show that modulation of the eNOS serine
1179 (S1179) phosphorylation site affects vascular reactivity and determines stroke size in
vivo. Transgenic mice expressing only a phosphomimetic (S1179D) form of eNOS show
greater vascular reactivity, develop less severe strokes, and have improved cerebral blood
flow in a middle cerebral artery occlusion model than mice expressing an
unphosphorylatable (S1179A) form. These results provide a molecular mechanism by
which multiple diverse cardiovascular risks, such as diabetes and obesity, may be centrally
integrated by eNOS phosphorylation in vivo to influence blood flow and cardiovascular
disease. They also demonstrate the in vivo relevance of posttranslational modification of
eNOS in vascular function.
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Generation of S1179A and S1179D eNOS transgenic mice. (A) Trans-
genic construct. A 1.6-kb fragment of the human eNOS promoter 
drives the bovine eNOS cDNA carrying the S1179D or S1179A muta-
tion, an HA tag, and the SV40 polyadenylation site. (B) Genotyping of 
transgenic and native eNOS genes by PCR. Primers E1 and E2 (see 
Methods) span an intron, so they amplify an 800-bp product from the 
endogenous WT eNOS gene but a 280-bp product from the S1179A 
and S1179D transgenes. Mice bred onto the homozygous eNOS KO 
background do not show the 800-bp product. (C) Western blot analysis 
of heart protein (60 μg) of WT, S1179D transgenic/eNOS KO (S1179D/
eNOS KO), and S1179A transgenic/eNOS KO (S1179A/eNOS KO) 
mice, using antibody directed against total eNOS.
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Subcellular localization of WT and transgenic 
eNOS. (A) En face immunostaining of the com-
mon carotid arteries using eNOS antibody shows 
localization of eNOS in perinuclear Golgi that are 
aligned along the long axes of the cells in the endo-
thelium. VE-cadherin (VE-cad) staining shows the 
outlines of the endothelial cell membranes. (B) En 
face immunostaining of the common carotid arter-
ies using anti-HA shows perinuclear staining in the 
Golgi apparatus in a pattern similar to that of eNOS 
immunostaining in WT mice. Expression levels of 
the transgene are comparable in the S1179A/eNOS 
KO mice and S1179D/eNOS KO mice. Original 
magnification, ×600.
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insulin  sensitivity,  as has been  reported  in eNOS 
homozygous and heterozygous KO mice (29, 30).





















of  increased  transgene  expression  that have been 
reported in some (28) but not other (12, 27) systems.





























Interactions between caveolin-1 (Cav-1) and eNOS are unaffected in mice carrying 
transgenes. En face immunostaining of the common carotid arteries using eNOS 
antibody and caveolin-1 antibody shows that interactions between eNOS and caveo-
lin-1 are unaffected in S1179D/eNOS KO mice and S1179A/eNOS KO mice. Original 
magnification, ×600.
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Effect of S1179A and S1179D eNOS mutations on cerebral infarct size. Mice were subjected to the filament model of MCA occlusion for 1 hour, 
followed by 23 hours of reperfusion. The brains were cut into 2-mm coronal sections and stained using 2,3,5-triphenyltetrazolium chloride. (A) 
Rostral to caudal distribution of infarct areas (mm2) in coronal sections. Abscissa shows the distance (mm) from the rostral surface of the brain. 
n = 7 mice for each group. *P < 0.05 versus corresponding sections from S1179A/eNOS KO mice; †P < 0.05 versus corresponding sections 
from eNOS KO mice using 1-way ANOVA. (B) Infarct volumes were determined by integrating the infarct areas in each section over the entire 
brain, using the indirect method, which corrects for edema. *P < 0.05 versus infarct volume from S1179A/eNOS and from eNOS KO mice using 
ANOVA. Neurologic scores for each group of mice are as follows: eNOS KO, 2.5; S1179A/eNOS KO, 2.67; S1179D/eNOS KO, 1.57; WT, 1.86. 
Kruskal-Wallis 1-way ANOVA on ranks showed a statistically significant difference between eNOS KO and S1179A/eNOS KO mice and WT and 
S1179D/eNOS KO mice (P < 0.05).
Figure 4
Effect of S1179D and S1179A mutations on vascular reactivity. (A) Left 
common carotid arteries were constricted with phenylephrine (10–5 M) 
and then subjected to increasing doses of ACh from 1 × 10–9 to 1 × 10–5 M. 
S1179A/eNOS KO mice, n = 8; S1179D/eNOS KO mice, n = 8; eNOS 
KO mice, n = 6; and WT mice, n = 8. *P < 0.01 by 1-way ANOVA; 
†P < 0.05 by 1-way ANOVA. (B) Left common carotid arteries were 
treated with l-NAME (3 × 10–4 M) for 30 minutes, constricted with phen-
ylephrine (10–5 M), and then subjected to increasing doses of SNP from 
1 × 10–9 to 1 × 10–5 M. Data are expressed as mean ± SEM.
research article












































































Effect of S1179A and S1179D eNOS mutations on cerebral blood flow. 
(A) Laser speckle contrast images in mice subjected to MCA occlu-
sion. Superimposed areas (blue) indicate regions with ≤30% resid-
ual blood flow. Imaging field dimensions are 6 × 8 mm. Thresholded 
images were recorded after 60 minutes of ischemia. (B) Composite 
graph showing the area of cortex with ≤20% (black) or 21–30% (blue) 
residual blood flow compared with preischemic baseline. *P < 0.05, 
comparing the area with ≤20% of residual blood flow of eNOS KO 
and S1179A/eNOS KO mice versus WT and S1179D/eNOS KO mice. 
CBF, cerebral blood flow.
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